logo

For the Inventor, By the Inventor

Epalinges, Switzerland

Donata Rimoldi

This inventor holds 6 USPTO granted patents. Top assignee: Ludwig Institute for Cancer Research Limited. Active years: 1999-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Donata Rimoldi. Retrieved from https://idiyas.com/inventor/donata-rimoldi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:

goldMedal6 out of 530 
 
Ludwig Institute for Cancer Research Limited
 patents

Years Active: 1999-2002

Loading Chart...
6 patents (USPTO):Explore Patents
1. 6497879 - Immunogenic compositions of tumor rejection antigen precursor MAGE-10 and an adjuvant (2002-12-24),
2. 6387698 - MAGE-10 encoding CDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof (2002-05-14),
3. 6221593 - Method for determining cancer by determining expression of MAGE-10 (2001-04-24),
4. 6174692 - MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof (2001-01-16),
5. 6153728 - Isolated tumor rejection antigen precursor MAGE-10 and compositions (2000-11-28),
6. 5908778 - Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, (1999-06-01),

Title: Donata Rimoldi: Innovator in Cancer Research

Introduction

Donata Rimoldi is a prominent inventor based in Epalinges, Switzerland. She has made significant contributions to the field of cancer research, particularly in the development of immunogenic compositions related to tumor rejection antigens.

Latest Patents

Donata Rimoldi holds a total of 6 patents. Her latest patents include innovative work on immunogenic compositions of tumor rejection antigen precursor MAGE-10. These patents encompass isolated cDNA molecules that encode the tumor rejection antigen precursor MAGE-10, the protein itself, and antibodies to it, along with their various uses.

Career Highlights

Rimoldi is associated with the Ludwig Institute for Cancer Research Limited, where she continues to advance her research in immunology and cancer treatment. Her work has been pivotal in understanding the mechanisms of tumor rejection and developing potential therapeutic strategies.

Collaborations

Throughout her career, Donata has collaborated with notable scientists such as Victor Jongeneel and Pierre G Coulie. These partnerships have enhanced her research and contributed to the advancement of cancer therapies.

Conclusion

Donata Rimoldi's innovative work in cancer research and her contributions to the field through her patents highlight her as a key figure in the scientific community. Her ongoing research promises to impact the future of cancer treatment significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…